Trial Profile
An Open, Randomised, Multi-centre Dose Ranging Phase II Study to Evaluate LAPDAP in Combination With Three Different Doses of Artesunate
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Chlorproguanil/dapsone/artesunate (Primary)
- Indications Falciparum malaria
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 21 Oct 2016 New trial record